Abstract

Inducible nitric oxide synthase (iNOS), accompanied with protumor and antitumor activity, has been studied in multiple cancers. However, the role of iNOS expression in osteosarcoma (OS) is far from being fully understood. In present work, iNOS levels were detected in OS tissues and cell lines. Colony formation assay, Transwell assay, and fow cytometer were used to assess proliferation, migration, invasion, and apoptosis abilities in vitro after iNOS inhibition. Western blotting determined the expressions of iNOS, MMP2, MMP9, C-MYC, Ki67, PCNA, and β-catenin. Mice transfected with OS cells were to evaluate tumor formation. IHC assay was to evaluate the expressions of iNOS and β-catenin in mice. The results showed that iNOS was upregulated in both OS tissues and cells compared with that in matched normal tissues or cells. And we found that proliferation, migration, and invasion numbers of OS cells were decreased, and apoptosis numbers of OS cells were increased after iNOS inhibition. MMP2, MMP9, C-MYC, Ki67, and PCNA levels were also reduced in OS cells treated with iNOS inhibition. Else, iNOS inhibition would suppress β-catenin expression in OS cells to regulate MMP2, MMP9, C-MYC, Ki67, and PCNA expressions. In addition, tumor formation, iNOS expression, and β-catenin expression were inhibited in mice transplanted with iNOS knockout OS cells. These results indicated that iNOS might be a potential therapeutic target for OS.

Highlights

  • Osteosarcoma (OS) is the most common primary malignant bone cancer, which occurs frequently in children and adolescents [1]

  • The results showed that Inducible nitric oxide synthase (iNOS) knockdown or iNOS inhibitor 1400 W suppressed the proliferation of Saos2 and 143B cells, as shown in Figures 2(a) and 2(b)

  • Saos2 and 143B cells treated with iNOS knockdown would significantly suppress the expressions of MMP2, MMP9, C-MYC, Ki67, and PCNA in OS cells, as shown in Figures 2(e) and 2(f)

Read more

Summary

Introduction

Osteosarcoma (OS) is the most common primary malignant bone cancer, which occurs frequently in children and adolescents [1]. Wnt/β-catenin pathway is involved in tumor genesis, proliferation, and chemotherapy resistance [11]. Some reports show that Wnt/β-catenin signaling participates in OS development. Wnt/β-catenin pathway activates the expression of RUNX2 gene that correlates with. In OS cells, conventional chemotherapeutics failure is associated with activation of Wnt/β-catenin signaling [17]. IWR-1 inhibits OS tumor growth via attenuating Wnt/βcatenin pathway [18]. It indicates that Wnt/β-catenin signaling can be a therapeutic target for OS metastasis. We hypothesize that iNOS plays a regulatory role in the development of OS via Wnt/βcatenin pathway and it might be a promising therapeutic target for OS

Materials and Methods
Results
Discussion
Conflicts of Interest
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call